Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting
20 September 2017 - 2:00PM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading
immunotherapy company focused on developing treatments for
autoimmune/inflammatory diseases and cancer, today announced a
planned poster presentation highlighting recent data from a
preclinical study evaluating dual ICOS/CD28 antagonists generated
by the Company’s vlgD™ platform at the upcoming 2017 American
College of Rheumatology Annual Meeting being held on November 3-8,
2017, in San Diego, CA.
Details of the poster presentation are as follows:
- Abstract Title: A Dual ICOS/CD28
Antagonist ICOSL Variant Ig Domain (vIgD™) Potently Suppresses
Mouse Collagen-Induced Arthritis and Human Xenograft Graft Vs. Host
Disease (GvHD)
- Session Title: Rheumatoid
Arthritis – Animal Models Poster II
- Date and Time: November 6, 2017,
at 9:00 a.m. – 11:00 a.m. PT
- Session Type: ACR Poster Session
B
- Abstract: #1328
The full abstract is available online at
https://www.rheumatology.org/Annual-Meeting under the “Abstracts”
section.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is focused on developing novel
protein-based immunotherapies using its proprietary Variant Ig
Domain™ vIgD™ platform technology. The vIgD platform is designed to
interact with multiple targets, including many present in the
immune synapse. Alpine’s vIgDs are developed using a process known
as directed evolution, which produces proteins capable of either
enhancing or diminishing an immune response and thereby may
potentially apply therapeutically to cancer, autoimmune, and
inflammatory diseases. Alpine has also developed TIP™ technology,
based on the vIgD platform, to potentially enhance engineered
cellular therapies. In October 2015, Alpine signed a worldwide
research and license agreement with Kite Pharma, Inc. (KITE) for up
to $535 million in up front and potential milestone payments plus
royalties on resulting sales. For more information visit
www.alpineimmunesciences.com/.
Forward-Looking Statements
This release contains forward-looking statements regarding
Alpine including Alpine’s platform technology, potential therapies,
clinical and regulatory objectives. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as “may,” “will,” “should,” “would,” “expect,” “plan,”
“intend,” and other similar expressions among others. Actual
results could differ materially and these statements are subject to
important risks, including that Alpine’s discovery-stage and
pre-clinical programs do not advance into the clinic or result in
approved products on a timely or cost-effective basis or at all.
Alpine’s pipeline programs, including the ALPN-101 program, are in
pre-clinical development, and the process by which a pre-clinical
therapeutic candidate could potentially lead to an approved
therapeutic is long and subject to significant risks and
uncertainties. Applicable risks and uncertainties include those
relating to our pre-clinical and potential clinical research and
other risks identified under the heading "Risk Factors" are
included in Alpine’s filings with the SEC. Alpine undertakes no
obligation to update forward-looking statements as a result of new
information or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170920005494/en/
Alpine Immune Sciences, Inc.Investor Relations:Pure
Communications, Inc.Courtney Dugan,
212-257-6723cdugan@purecommunications.comorMedia Relations:W2O
GroupJennifer Paganelli, 347-658-8290jpaganelli@w2ogroup.com
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024